Full-Time

Project and Portfolio Management

Project Portfolio Management, Reporting & Administration

Posted on 5/9/2026

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

King of Prussia, PA, USA + 3 more

More locations: Australia | Melbourne VIC, Australia | Noida, Uttar Pradesh, India

In Person

Category
Business & Strategy (2)
,
Required Skills
Six Sigma
Requirements
  • Bachelor's degree, preferably in a related technical subject or advanced degree in business or industry-related subject
  • 8+ years demonstrated process improvement and measurement experience especially utilizing performance measurement, process mapping and business process re-engineering
  • Demonstrated experience in data management as a data steward
  • Demonstrated experience in process improvement concepts, tools and techniques, measurement definition, process mapping and business process re-engineering
  • Verifiable experience in influencing and leading organizational change to implement new/improved processes and measures
  • Demonstrated ability to act as an advisor to leadership and internal partners providing insights into the enterprise’s performance and process through data, metrics and analytics as well as creative problem solving
  • Experienced in developing business requirements, developing instructional/ procedural documentation and presentations particularly around PPM and measurements
  • Experienced in CA Project and Portfolio Management or other equivalent tool desired
  • Excellent interpersonal verbal and written communication skills interfacing with management, process owners and project/portfolio teams
  • Strong presentation skills to all levels of the organization
  • Understanding of lean manufacturing / Six Sigma concepts desired
  • Travel up to 20%
  • Different qualifications or responsibilities may apply based on local legal and/or educational requirements.
Responsibilities
  • Create PPM information strategy, plan and design view for the PPM processes, data and systems while negotiating common metrics/KPIs with the PPM business process owners
  • Manage operational activities to support an efficient and sustainable usage of the PPM system
  • Deploy leading practice reports to improve efficiency and productivity by proposing changes to existing processes and workflows including automation capabilities
  • Develop, promote, support and improve repeatable processes, methods, measures and leading practices across the enterprise to provide reliable data to leaders to enable value-added business decisions
  • Act as a data steward for data in the PPM system
  • Support, design, and architect the definition of PPM information management principles, guidelines, patterns, and standards around data accuracy, reporting and measurements
  • Monitor the implementation of PPM measurement systems throughout the enterprise. Provide technical mentoring, guidance and clarification to other process experts and implementation resources
  • Analyze existing measurement systems to understand and document data elements, relationships, data flow, dependencies, and related interfaces
  • Monitor the enterprise PPM reporting development pipeline in line with agreed priorities and ensure consistent maintenance of documentation
  • Develop new reports and enhancements to effectively communicate PPM data trends, patterns and insights to enable better decision making
  • Oversee and coordinate operational PPM tool activities and act as coach to establish consistent knowledge sharing across the team
  • Lead the measurement process improvement concepts/methodologies/tools/principles development, training and guidance
  • Gather and document business and technical requirements. Use analytical and statistical methods to evaluate business data in the PPM process and system to ensure accuracy of data measured
  • Engage with business stakeholders to support functional solution identification in close collaboration with I&T to align on technical feasibility
  • Lead the overall coordination of release testing activities between I&T, business and the responsible User Acceptance Test Owner
  • Develop, use, and review work aids, such as process descriptions, checklists, templates and guides to assist users with implementing defined measurement processes
  • Drive the identification and implementation of measures to simplify and automate support and training approaches to improve efficiency and effectivity for PPM end-users
  • Perform root cause, performance trend analysis and work simplification studies in order to develop appropriate measurement control changes. Analyze measurement/KPI standards and metrics to provide solutions for improvements. Review analysis findings to recommend appropriate changes in process, requirements or data approach
  • Survey and analyze leading best practice benchmarks for measurement and data techniques and processes. Create, update and maintain measurement related documentation.Develop metrics that provide value-add decision data for projects, portfolios and leaders. Prioritize and implement measurement and data change requirements based on critical business need
  • Lead and drive process and measurement improvement plans for PPM affecting multiple functions and/or systems. Identify and implement changes to corporate and organizational level PPM measurement processes to improve productivity and reduce risk
Desired Qualifications
  • CA Project and Portfolio Management or other equivalent tool desired
  • Understanding of lean manufacturing / Six Sigma concepts desired

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
  • KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
  • VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.

What critics are saying

  • Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
  • Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
  • Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.

What makes CSL unique

  • CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
  • CSL Seqirus dominates influenza vaccines with global production scale.
  • CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at CSL who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients